Leclaza to receive first monitoring for PVA negotiations

in Q4, 91 drugs will be monitored including homegrown drugs such as Kanarb, Supect, and Pelubi

The National Health Insurance Service disclosed drugs subject to monitoring for Type A and Type B of the Price-Volume Agreement negotiations in the fourth quarter of 2022.

 

The list is attracting attention as Yuhan Corp’s novel non-small-cell lung cancer drug Leclaza was also selected for monitoring, as well as domestic homegrown drugs such as Kanarb, Supect, and Pelubi.

 

A total of 91 drugs that are subject to monitoring for PVA negotiations in the 4th quarter this year were disclosed in advance on NHIS’s webpage on the 20th.

 

The NHIS selects drugs that are subject to monitoring for PVA Type A and B negotiations every quarter.

 

Drugs receive negotiations under 'Type A' when the claims amount in their same therapeutic class exceeds the expected claims amount that the company had agreed upon with the NHIS through negotiations by over 30%.

 

Leclaza will also be monitored for Type A negotiations.

 

As Leclaza was listed on July 1st last year, its rate of increase will be calculated by comparing the claims amount accrued from July 1st last year to June 30th this year with the expected claims amount.

 

Leclaza’s expected claims amount is known to be KRW 14.1 billion.

 

However, based on IQVIA data, Yuhan Corp had earned KRW 11 billion in the period.

 

Therefore, the analysis is that the drug will not be subject to negotiations, but as the amount of the actual claims may differ, it is difficult to prejudge whether it will be included in the negotiation list.

 

Many novel homegrown drugs were also listed for monitoring for ‘Type B’ PVA negotiations, which are applied to drugs whose maximum amount had already been adjusted according to Type A PVA.

 

Boryung Pharmaceutical’s hypertension treatment Karnab is one representative drug that will receive monitoring in Q4.

 

Also, Il-Yang Pharmaceuticals’ leukemia treatment Supect, and Daewon Pharm’s antipyretic, anti-inflammatory, pain reliever Peluvi were included for monitoring this quarter.

 

Among imported novel drugs, the oral anticoagulants Xarelto and Lixiana, and immunotherapy drugs Opdivo and Yervoy whose use has increased greatly recently were listed as monitoring subjects.

 

The claims amount of the previous year and the year before are compared for drugs that are subject to ‘Type C’ PVA negotiations.

 

172 items have received negotiations under Type C and unilaterally discounted on the 1st of this month.